Compare FOR & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | ALMR |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2007 | 2026 |
| Metric | FOR | ALMR |
|---|---|---|
| Price | $28.66 | $25.05 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $32.67 | N/A |
| AVG Volume (30 Days) | 138.6K | ★ 221.5K |
| Earning Date | 04-21-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $1,662,400,000.00 | N/A |
| Revenue This Year | $0.34 | N/A |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $17.77 | ★ N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $22.81 | $21.58 |
| 52 Week High | $32.06 | $29.43 |
| Indicator | FOR | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 49.46 |
| Support Level | $24.05 | $23.88 |
| Resistance Level | $29.44 | $28.35 |
| Average True Range (ATR) | 1.04 | 1.99 |
| MACD | -0.15 | -0.28 |
| Stochastic Oscillator | 55.94 | 17.18 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.